It is certain that chemoimmunotherapy using chemotherapeutic agents that directly kill tumor cells to induce ICD to achieve enhanced anti-tumor immunity is feasible, and CD4+ T-cell-based immunotherapy is also an effective strategy for controlling tumor progression and recurrence, and our experiments have expanded the options for tumor immunotherapy. The gene discussed is CD4; the disease is neoplasm.